Sight Sciences, Inc. (SGHT)

US — Healthcare Sector
Peers: RXST  AXGN  TMCI  LUNG  OFIX  RPID  CTKB  EVCM 

Automate Your Wheel Strategy on SGHT

With Tiblio's Option Bot, you can configure your own wheel strategy including SGHT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SGHT
  • Rev/Share 1.5229
  • Book/Share 1.5135
  • PB 2.2002
  • Debt/Equity 0.0
  • CurrentRatio 10.4691
  • ROIC -0.4247

 

  • MktCap 172167993.0
  • FreeCF/Share -0.4765
  • PFCF -7.0451
  • PE -3.4578
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.5462

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SGHT UBS -- Buy -- $5.5 Dec. 6, 2024
Initiation SGHT Lake Street -- Buy -- $10 Aug. 21, 2024

News

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
SGHT
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research

Read More
image for news Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

About Sight Sciences, Inc. (SGHT)

  • IPO Date 2021-07-15
  • Website https://www.sightsciences.com
  • Industry Medical - Devices
  • CEO Paul Badawi
  • Employees 216

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.